Zobrazeno 1 - 8
of 8
pro vyhledávání: '"329"'
Autor:
Romain Guieze, Anne Calleja, Loic Ysebaert, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Fontanet Bijou, Anne Quinquenel, Annie Brion, Kamel Laribi
Publikováno v:
61st Annual Meeting and Exposition of the American Society of Hematology
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
Ibrutinib has revolutionized the management of RR CLL in the past 5 years, improving overall survival (OS) over standard chemo-immunotherapies (CIT) in the registration trials HELIOS and RESONATE. Recently, based on these two studies, a score has bee
Autor:
Yanmin Zhao, Lizhen Liu, Yi Chen, Ying Lu, Jian Yu, Kang Yu, He Huang, Xiaoyu Lai, Jimin Shi, Huarui Fu, Fei Gao, Baodong Ye, Lieguang Chen, Jianping Lan, Xiaolu Song, Yi Luo
Publikováno v:
Blood. 138:1825-1825
Objective Hematopoietic stem cell transplantation (HSCT) is one of the most efficient treatments for hematologic malignancies. However, relapse remains the main cause of transplant failure. In myeloid neoplasia, the long-term survival for patients wh
Autor:
Tony Reiman, Donna E. Reece, Eshetu G. Atenafu, Martha L Louzada, Christopher P. Venner, Muhammad Aslam, Michael Sebag, Kevin W. Song, Arleigh McCurdy, Richard Leblanc, Esther Masih-Khan, Julie Stakiw, Darrell White, Engin Gul, Rami Kotb, Victor H Jimenez-Zepeda
Publikováno v:
Blood. 134:1886-1886
Lenalidomide in combination with dex (Len + dex) was introduced as treatment for relapsed/refractory myeloma in Canada over a decade ago; more recently, Len has been routinely available as part of first-line therapy, both in transplant-eligible patie
Autor:
Erin Morris, John S. Holcenberg, F. Leonard Johnson, Stanton Goldman, Raymond J. Hutchinson, Jerry Z. Finklestein, Susan G. Kreissman, Elizabeth Harvey, Conrad Tou, Mitchell S. Cairo
Publikováno v:
Blood. 97:2998-3003
Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin
Autor:
Russell Saal, Paula Marlton, Luen Bik To, Thomas J. Gonda, Sarah C Bray, Kyaw Ze Ya Maung, Mahmoud A. Bassal, Devinder Gill, James X Gray, Adam D. Ewing, Ian D. Lewis, Evgeny A. Glazov, Debora A. Casolari, Emma L. Duncan, Paul Leo, Richard J D'Andrea, Anna L. Brown
Publikováno v:
Blood. 128:41-41
While there have been extensive studies to define the roles of recurrent somatic mutations in AML, the contribution of germline variants to AML initiation and progression is less well established. DNA repair disorders often predispose patients to dev
Autor:
Kathryn Humphrey, Alexandra Bazeos, Francine Swann, Nelson Kinnersley, Othman Al-Sawaf, Noelle Crompton, Craig Gower, Günter Fingerle-Rowson, Peter Trask, Mark Dixon, Valentin Goede
Publikováno v:
Blood. 128:4352-4352
BACKGROUND The evaluation of response to therapy in CLL is widely assessed according to the iwCLL guidelines which define progressive disease (PD) as advancing lymphocytosis, lymphadenopathy, organomegaly, cytopenias or histological transformation (H
Autor:
Neeraj Agarwal, Jason Li, Nicole Hagner, Margaret M. Woo, Martijn P. Lolkema, Sunil Sharma, Emile E. Voest, Petronella O. Witteveen, Maria Grazia Porro, Dagmar Hess, Derek Mires, Sue-zette Valera
Publikováno v:
Blood. 118:5001-5001
Abstract 5001 Panobinostat is a potent class I/II/IV oral pan-deacetylase inhibitor which has shown promising clinical activity in patients with multiple myeloma and myelofibrosis, some with compromised renal and hepatic functions. The metabolism med
Publikováno v:
Blood. 104:4939-4939
Background: Zoledronic acid is a new-generation bisphosphonate with demonstrated efficacy and safety in the treatment of bone lesions in patients with multiple myeloma and solid tumors using a monthly regimen of 4 mg infused over 15 minutes. This pha